J Bone Metab.  2013 May;20(1):17-23. 10.11005/jbm.2013.20.1.17.

National Healthcare Budget Impact Analysis of the Treatment for Osteoporosis and Fractures in Korea

Affiliations
  • 1Department of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, Korea.
  • 2Department of Orthopaedic Surgery, Chung-Ang University College of Medicine, Seoul, Korea.
  • 3Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 4Department of Obstetrics and Gynecology, The Catholic University of Korea, College of Medicine, Seoul, Korea. ymandi@ksog.org

Abstract

BACKGROUND
This study was to determine the impact on the national healthcare expenditure for the treatment of osteoporosis and fractures if the coverage period for osteoporosis medication was extended from maximum a year to continuous period as required.
METHODS
Preserving the current reimbursement guidelines, maximum one year's coverage for osteoporosis medication was set as scenario A. Continuous coverage for patients who require medication was set as scenario B. As costs of medical service utilization are paid by the Korean National Health Insurance Program, all items were investigated and analyzed from the payer's perspective. The combined treatment costs for osteoporosis and osteoporotic fractures were assessed for each scenario.
RESULTS
Over five years the cost of osteoporosis medication in scenario A will increase from 184.3 billion KRW to 204.6 billion KRW. The cost of osteoporotic fracture treatment will increase from 1,037.3 billion KRW to 1,822.7 billion KRW. In scenario B, the cost of osteoporosis medication will increase from 209.5 billion KRW to 388.1 KRW. The cost of osteoporotic fracture treatment will increase from 600.0 billion KRW to 1,054.3 billion KRW. The result showed savings of 2.50 trillion KRW cumulatively for five years when reimbursement coverage for osteoporosis treatments is extended from one year to as long as it's clinically required.
CONCLUSIONS
This study demonstrates that effective osteoporosis management through appropriate insurance coverage for osteoporosis medication should be considered not only for the patient's viewpoint, but in terms of national insurance budget as well.

Keyword

Economics; Fractures bone; Health expenditures; Osteoporosis; Republic of Korea

MeSH Terms

Budgets
Delivery of Health Care
Health Care Costs
Health Expenditures
Humans
Income
Insurance
Insurance Coverage
Korea
National Health Programs
Osteoporosis
Osteoporotic Fractures
Republic of Korea

Figure

  • Fig. 1 Total national budget impact by each scenario shows that scenario B saved up to approximately 2,498 billion KRW in the national health budget during five year time frame. Sce A. OP Exp, scenario A. osteoporosis expenditure; Sce A. Fx Exp, scenario A. fracture expenditure; Sce A. Total Exp, scenario A. total expenditure; Sce B. OP Exp, scenario B. osteoporosis expenditure; Sce B. Fx Exp, scenario B. fracture expenditure; Sce B. Total Exp, scenario B total expenditure.


Cited by  7 articles

Epidemiology of osteoporosis in Korea
Yong-Chan Ha
J Korean Med Assoc. 2016;59(11):836-841.    doi: 10.5124/jkma.2016.59.11.836.

Undertreatment of Osteoporosis Following Hip Fractures in Jeju Cohort Study
Sang-Rim Kim, Yong-Geun Park, Soo Yong Kang, Kwang Woo Nam, Yong-Gum Park, Yong-Chan Ha
J Bone Metab. 2014;21(4):263-268.    doi: 10.11005/jbm.2014.21.4.263.

Osteoporotic Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research
Je-Hyun Yoo, Seong-Hwan Moon, Yong-Chan Ha, Dong Yeon Lee, Hyun Sik Gong, Si Young Park, Kyu Hyun Yang
J Bone Metab. 2015;22(4):175-181.    doi: 10.11005/jbm.2015.22.4.175.

Vitamin D Deficiency Is Highly Concomitant but Not Strong Risk Factor for Mortality in Patients Aged 50 Year and Older with Hip Fracture
Gyeong-Hak Lee, Jung-Won Lim, Yong-Gum Park, Yong-Chan Ha
J Bone Metab. 2015;22(4):205-209.    doi: 10.11005/jbm.2015.22.4.205.

Health-related Quality of Life in Accordance with Fracture History and Comorbidities in Korean Patients with Osteoporosis
Hye-Young Kwon, Yong-Chan Ha, Jun-Il Yoo
J Bone Metab. 2016;23(4):199-206.    doi: 10.11005/jbm.2016.23.4.199.

Inadequate Dietary Calcium and Vitamin D Intake in Patients with Osteoporotic Fracture
Dong Sik Yoon, Young-Kyun Lee, Yong-Chan Ha, Ha-Young Kim
J Bone Metab. 2016;23(2):55-61.    doi: 10.11005/jbm.2016.23.2.55.

Clinical Utility of Biochemical Marker of Bone Turnover: Fracture Risk Prediction and Bone Healing
Byung-Ho Yoon, Woojin Yu
J Bone Metab. 2018;25(2):73-78.    doi: 10.11005/jbm.2018.25.2.73.


Reference

1. Park C, Ha YC, Jang S, et al. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011. 29:744–751.
Article
2. Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone. 1992. 13:Suppl 1. S7–S15.
Article
3. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int. 2005. 16:Suppl 2. S8–S17.
Article
4. Mullen JO, Mullen NL. Hip fracture mortality. A prospective, multifactorial study to predict and minimize death risk. Clin Orthop Relat Res. 1992. 280:214–222.
5. Randell AG, Nguyen TV, Bhalerao N, et al. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. 2000. 11:460–466.
Article
6. National Health Insurance Service. National health insurance statistical yearbook. 2012. cited by 2012 August 10. Available from: http://www.nhic.or.kr/portal/site/main/MENU_WBDDG0201/.
7. Ministry of Health and Welfare. Details (medicines) on application standards of medical care benefit and methods. 2010. cited by 2012 December 14. Available from: http://www.mw.go.kr/front_new/jb/sjb0402vw.jsp?PAR_MENU_ID=03&MENU_ID=030402&page=15&CONT_SEQ=258980&SEARCHKEY=DEPT_NM&SEARCH_FLAG=03.
8. National Health Insurance Service. National health insurance statistical yearbook. 2010. cited by 2012 August 10. Available from: http://www.nhic.or.kr/portal/site/main/MENU_WBDDG0201.
9. Langdahl BL, Harsløf T. Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis. 2011. 3:17–29.
Article
10. Black DM, Thompson DE, Bauer DC, et al. FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000. 85:4118–4124.
Article
11. Pueyo MJ, Larrosa M, Suris X, et al. Cost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in Catalonia. Reumatol Clin. 2012. 8:128–134.
Article
12. Muller D, Pulm J, Gandjour A. Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review. Value Health. 2012. 15:284–298.
Article
13. Hiligsmann M, McGowan B, Bennett K, et al. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health. 2012. 15:604–612.
Article
14. Borgstrom F, Kanis JA. Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008. 22:885–900.
Article
15. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int. 2007. 18:9–23.
Article
16. Johnell O, Jonsson B, Jonsson L, et al. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics. 2003. 21:305–314.
Article
17. Kim SR, Ha YC, Park YG, et al. Orthopedic surgeon's awareness can improve osteoporosis treatment following hip fracture: a prospective cohort study. J Korean Med Sci. 2011. 26:1501–1507.
Article
18. Colon-Emeric C, Yballe L, Sloane R, et al. Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture. J Am Geriatr Soc. 2000. 48:1261–1263.
Article
19. ICANN Accredited Registrar. Uk-domains with anycastnamservers. 2011. cited by 2012 December 14. Available from: www.nic.org.uk.
20. Australian Government Department of Health and Ageing. Pharmaceutical benefits scheme (PBS). 2012. cited by 2012 December 14. Available from: www.pbs.gov.au.
21. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010. 16:1016–1019.
Article
22. Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008. 149:404–415.
Article
23. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008. 19:399–428.
Article
24. Health Insurance Review & Assessment Service. Drug reimbursement criteria. 2012. cited by 2012 December 14. Available from: http://www.hira.or.kr/dummy.do?pgmid=HIRAA910001000000&cmsurl=/cms/information/04/01/01/druginfo_notice.html.
Full Text Links
  • JBM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr